Trial-anchored psychedelic practice guidance

Preview competencies (3)

• Cardiovascular safety screening

  Screen for cardiovascular risk before treatment because ibogaine may prolong the QT interval and has been linked to arrhythmias and deaths. Exclude or carefully manage patients with cardiac disease and other risk factors.

• Knowledge of toxicity profile and cardiac risk

  Understand that ibogaine has a significant toxicity profile, especially cardiotoxicity. Fatalities have been temporally associated with use, often in the setting of medical comorbidity, co-use, or electrolyte imbalance.

• Informed consent and ethical use in uncertain evidence

  Use ibogaine only after a careful discussion of uncertain efficacy, limited research, and known risks. Ethical practice requires transparent communication about the experimental nature of treatment and the absence of robust clinical standards.

Preview competencies (1)

• Study record management literacy

  The therapist/facilitator should understand clinical trial recordkeeping terminology and the requirements for submitting study registration or results information. This supports accurate coordination within the trial environment.

Preview competencies (1)

• Source extraction not possible

  The provided source text does not contain the article content needed to identify therapist or facilitator competencies. It only includes a Wiley cookie/login page and site boilerplate.

Preview competencies (3)

• Withdrawal monitoring

  Monitors acute opioid withdrawal symptoms before and after treatment using structured measures to evaluate detoxification response.

• Opioid use disorder assessment

  Understands the clinical profile of opioid use disorder and identifies individuals with opioid dependence who may be considered for ibogaine-based detoxification in observational or treatment settings.

• Substance use outcome tracking

  Collects and interprets follow-up data on opioid use and related functioning over time after treatment.

Preview competencies (3)

• Registry data compliance awareness

  Awareness of the need to use official data element definitions when submitting registration or results information. This reflects adherence to accurate and compliant trial reporting practices.

• Safety and role-appropriateness judgment

  Ability to recognize when a source does not provide enough information to infer clinical safety responsibilities or therapist competencies. This prevents unsupported claims about monitoring or intervention delivery.

• Study documentation review

  Ability to review publicly available study documentation to determine whether therapist or facilitator competencies are specified. This includes recognizing when the source does not contain sufficient detail for extraction.

Preview competencies (1)

• Trial record management literacy

  Understands the ClinicalTrials.gov study record context and the role of study record managers. This includes awareness of how study information is organized and submitted in a regulated trial registry environment.

Preview competencies (1)

• Clinical trial record management literacy

  The facilitator should understand how study records are maintained and how to refer to official data element definitions when managing registration or results information. This supports accurate, compliant handling of trial documentation.

Preview competencies (3)

• Cardiac safety monitoring

  Monitor cardiac status closely during and after ibogaine administration because clinically relevant QTc prolongation can occur and may persist beyond the immediate dosing period. Continuous or repeated assessment is required to detect dangerous arrhythmias and bradycardia early.

• Neurologic adverse effect monitoring

  Monitor for cerebellar toxicity and gait disturbance because severe transient ataxia was observed in all patients in the study. The facilitator must be able to detect impaired coordination and prevent falls or injury.

• Use within a medically controlled setting

  Administer the intervention only in a setting capable of medical monitoring and emergency response. The study occurred in a university medical center psychiatry department, underscoring the need for a controlled clinical environment.

Preview competencies (1)

• Study record management literacy

  Therapist/facilitator should understand the study record context and the administrative vocabulary used in the trial registry. This supports accurate interpretation of study-related documentation and responsibilities.

Preview competencies (3)

• Cardiac risk monitoring

  Monitor for ibogaine-associated cardiac toxicity, especially QTc prolongation and risk of torsades de pointes. This includes baseline exclusion screening, frequent ECG surveillance, and escalation when QTc becomes markedly prolonged.

• CYP2D6 genotype-informed dosing

  Use pharmacogenetic information to anticipate altered ibogaine metabolism and exposure. The study identifies CYP2D6 activity as a major determinant of ibogaine clearance.

• Informed consent and ethics

  Ensure participants understand the experimental nature, risks, and alternatives before treatment. The study was conducted under ethics approval with written informed consent.

Preview competencies (3)

• Clinical trial record interpretation

  Ability to understand and use information from a ClinicalTrials.gov study record. This includes recognizing study identifiers, registry language, and metadata relevant to a protocol or intervention context.

• Protocol information management

  Ability to work with study record requirements and data elements in a structured and compliant way. This supports accurate documentation and communication within a trial setting.

• Ethical data handling

  Responsibility to use study information appropriately and in accordance with registry expectations. This includes respecting the limits of what can be inferred from the record text alone.

Preview competencies (3)

• Patient monitoring during ibogaine administration

  Monitors patients closely during treatment because serious adverse outcomes may occur. Safety monitoring is essential given that one participant died during treatment in the study.

• Opioid withdrawal assessment

  Assesses opioid withdrawal symptoms before and immediately after treatment. Uses symptom change to help evaluate acute treatment effects and patient status.

• Addiction severity and outcome assessment

  Measures substance use and broader addiction-related functioning over time. Tracks longitudinal outcomes to determine treatment response.

Preview competencies (3)

• Cardiac safety and QT monitoring

  Understands and monitors concentration-related cardiac risk, especially QTc prolongation, in participants receiving noribogaine or similar agents. Uses ECG findings to support safe trial conduct and participant protection.

• Controlled-dose administration

  Administers single ascending doses within a randomized, double-blind, placebo-controlled framework. Follows protocol-specific dosing procedures to preserve blinding and participant safety.

• Pharmacokinetic literacy

  Understands core pharmacokinetic concepts needed to interpret study findings and guide safety observation. Recognizes dose-linear exposure changes and elimination characteristics relevant to monitoring windows.

Preview competencies (0)

Competency extraction pending.

Preview competencies (3)

• Evidence appraisal

  Understands the strength and limitations of the existing literature on ibogaine for opioid use disorder. Can distinguish case-report evidence from rigorous clinical trial evidence and communicate uncertainty appropriately.

• Ethical risk communication

  Communicates the experimental and unregulated nature of ibogaine treatment honestly. The source highlights an ibogaine subculture offering unregulated preparations, which creates an ethical duty to disclose uncertainty and risks.

• Ibogaine-informed case selection

  Can evaluate whether ibogaine is being considered in the context of a highly selected clinical case, based on the source’s description of a severe, treatment-refractory patient. This includes understanding the limited evidence base and the need for careful patient selection.

Preview competencies (3)

• Emergency response readiness

  Be prepared to recognize medical deterioration and summon emergency help immediately. The manual states that providers who cannot call for emergency assistance should not provide ibogaine therapy.

• Pre-treatment medical screening

  Conduct a basic medical intake that identifies major medical, psychiatric, and substance-use risks before ibogaine is administered. Screening is intended to reduce preventable adverse events and determine whether treatment is appropriate.

• Cardiac risk assessment

  Evaluate cardiac safety before treatment using history, vital signs, and electrocardiography. The manual repeatedly emphasizes heart-related screening because of documented fatalities and the risk of sudden cardiovascular events.

Preview competencies (3)

• Risk-benefit decision making

  The provider must be able to judge whether a patient is an appropriate candidate and when treatment should be deferred or declined. Decisions should reflect absolute exclusions, relative risks, and the need for specialist review.

• Cardiac monitoring

  Providers must continuously monitor cardiac status because ibogaine can prolong QTc, alter T-wave morphology, and precipitate arrhythmias. This includes observation before, during, and after dosing.

• Psychological assessment and screening

  Providers must be able to assess psychological suitability and identify risk factors before treatment. Careful screening is presented as the most important factor in minimizing harm.

Preview competencies (3)

• Informed consent and voluntariness

  Ensure participation is voluntary and based on an informed understanding of the risks, benefits, and requirements of ibogaine-assisted therapy and follow-up. Verify that the participant is not coerced and agrees to ongoing contact and aftercare expectations.

• Confidentiality and data protection

  Protect participant identity by removing identifying information and limiting access to coded data. The study requires de-identified handling of information and separation of analysis from identifying details.

• Dose administration and session monitoring

  Implement the protocol’s dosing and observation procedures while continuously monitoring the participant’s physiological and behavioral status. This includes test dosing, vitals checks, and ongoing observation during the prolonged session.